title: Comment on "Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients," by Garbino et al.
authors.forename: H K F
authors.initials: HK
authors.lastname: Van Saene
authors.forename: L
authors.initials: L
authors.lastname: Silvestri
authors.forename: A
authors.initials: A
authors.lastname: Petros
authors.forename: M
authors.initials: M
authors.lastname: Viviani
authors.forename: M A
authors.initials: MA
authors.lastname: de la Cal
authors.forename: D F
authors.initials: DF
authors.lastname: Zandstra
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use; D002177:Candidiasis / Q000150:complications / Q000517:prevention & control*; D016638:Critical Illness; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D009503:Neutropenia; D010919:Placebos; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents; D010919:Placebos; D015725:Fluconazole